brintellex
ValprolBanner
Annals of Indian Academy of Neurology
  Users Online: 2268 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
 
REVIEW: SYSTEMATIC (SYSTEMATIC REVIEW OF A SUBJECT)
Ahead of Print

What is new in idiopathic inflammatory myopathies: Mechanisms and therapies


1 Department of Neurology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India
2 Department of Neurology, Dr. L H Hiranandani Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Satish V Khadilkar,
Dean, BHIMS and Professor and Head, Department of Neurology, Bombay Hospital Institute of Medical Sciences, Room 110, First Floor, New Wing, Bombay Hospital, 12 New Marine Lines, Mumbai - 400 020, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aian.AIAN_400_19

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders that cause muscle weakness and also have extramuscular manifestations involving various organ systems; namely the lung, skin, heart, and joints. Previously classified broadly as dermatomyositis (DM) and polymyositis now the spectrum of the disease has evolved into more clinical subtypes. There are now five clinicoserological subtypes recognized worldwide DM, antisynthetase syndrome (AS), overlap myositis (OM), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis. Each of these subtypes has a unique phenotype and specific antibodies associated. With the evolving treatment options from the use of immunosuppressive medications to the use of targeted therapy with biologic agents, and further understanding of the pathogenesis of inflammatory myositis, we may have more effective treatment options. We discuss in this review, various myositis-associated antibodies associated with each clinicoserological subtype of IIM and their role. We also describe the evolving therapies and the evidence for the newer biologic therapies in the treatment of IIMs.


Print this article
 [NEXT]
 [PREV]
 Table of Contents

  Search Pubmed for
 
    -  Khadilkar SV
    -  Dhamne MC
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed162    
    PDF Downloaded98    

Recommend this journal